Date: Sep 25, 2013 Source: PR Newswire (
click here to go to the source)
 |
LOS ANGELES, Sept. 25, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today it launched its first crowdfunding campaign to raise funding to accelerate the development of its cancer-fighting drug that is planned to boost the survival and quality of life for patients with ovarian cancer, breast cancer, prostate cancer, and other cancers, an initiative facilitated by the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California; Three Two One Productions; When You Wish; and the women who share their ovarian cancer experiences: Diem Brown, Entertainment reporter and former contestant on MTV's Real World/Road Rules Challenge, who shares her experience of being diagnosed with ovarian cancer at age 23 (The MEDGift Foundation); Amy Cohen Epstein who watched her mother, Lynne Cohen, suffer and succumb from ovarian cancer (Lynne Cohen Foundation); Paulinda Schimmel Babbini who saw her daughter, Robin, diagnosed with ovarian cancer at age 17 and lose her life at age 20 (The Ovarian Cancer Circle); and, Diane Balma, former executive at the Susan G. Komen For the Cure, explains the importance of involving the general public in supporting medical research for cancer.
Through the miracle of the internet and social media the public now has the opportunity to directly fund cutting-edge cancer research and drug development. To donate to the company's drug development program simply click on the following WhenYouWish link: http://www.whenyouwish.com/project/boostcancersurvivalrates
1 minute of your time and a donation of your choosing will make a difference.
Applied Integrin Sciences, Inc. scientists' at the University of Southern California Keck School of Medicine and the USC Norris Comprehensive Cancer Center discovered a novel cancer-fighting therapeutic drug has demonstrated effective reduction of tumor growth and progression on six aggressive tumors: triple negative breast cancer, ovarian cancer, primary prostate cancer, prostate bone metastasis, melanoma, and brain cancer -- glioblastoma. The company identified a new approach to treating ovarian cancer using its first cancer drug candidate that was funded by the National Cancer Institute of the National Institutes of Health, and is beginning the final research steps required by the FDA prior to submitting its application to conduct human clinical trials.
The company's goal is to complete clinical drug development and achieve the same results as obtained in the laboratory. If achieved this novel cancer treatment could change the current standard of care and improve patient survival and quality of life. And if demonstrated safe in early clinical trials, the company also intends to embark on clinical development for other cancer indications including breast and prostate cancers.
About Applied Integrin Sciences
Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life. The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin modulating recombinant protein therapeutics that reduce tumor growth and progression in primary tumors, newly growing tumor-induced vasculature, and metastatic foci. The company is currently evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the NIH, as its first indication. For additional information about the company, please visit www.integrins.com.
About the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California
The Alfred E. Mann Institute for Biomedical Engineering was established at the University of Southern California in 1998. Its mission is to help bridge the gap between biomedical innovation and the creation of commercially-successful medical products to improve and save lives.
About Three Two One Productions
Three Two One Productions is a company led by seasoned storytellers from film and television who create cutting edge business, bios, and legacy videos.
About When You Wish
When You Wish is a leading Internet "crowdfunding" company that combines payment processing and publishing tools to help entrepreneurs raise money online for their ideas or causes.
Source: Applied Integrin Sciences, Inc.
Public Relations.
(805) 715-4166
Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166, info@integrins.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Applied Integrin Sciences, Inc.
